Profile data is unavailable for this security.
About the company
Clinuvel Pharmaceuticals Limited is a global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. The Company is engaged in managing and expanding commercial distribution of its lead drug candidate, SCENESSE, in Europe, the United States, Israel, and Australia for the treatment of a rare, genetic metabolic disorder, erythropoietic protoporphyria (EPP). The Company’s pipeline includes PRENUMBRA, NEURACTHEL, CUV9900, and Parvysmelanotide (VLRX001). PRENUMBRA is a liquid (non-solid) injectable formulation of afamelanotide designed to provide a flexible dose of afamelanotide, a synthetic analogue of natural a-melanocyte stimulating hormone. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH), for neurological, endocrinological and degenerative disorders.
- Revenue in AUD (TTM)87.29m
- Net income in AUD30.15m
- Incorporated1999
- Employees16.00
- LocationClinuvel Pharmaceuticals LtdLevel 22, 535 Bourke StreetMELBOURNE 3000AustraliaAUS
- Phone+61 39660-4900
- Fax+61 39660-4909
- Websitehttps://www.clinuvel.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dimerix Ltd | 181.28k | -10.87m | 175.87m | 0.00 | -- | 79.43 | -- | 970.17 | -0.0294 | -0.0294 | 0.0005 | 0.004 | 0.0169 | -- | 0.7586 | -- | -101.36 | -70.77 | -128.88 | -110.81 | -- | -- | -5,994.52 | -61,882.73 | -- | -- | 0.4541 | -- | 1,452.32 | 12.76 | -31.57 | -- | -8.26 | -- |
| Race Oncology Ltd | 885.59k | -11.17m | 204.85m | -- | -- | 9.88 | -- | 231.32 | -0.069 | -0.069 | 0.0055 | 0.125 | 0.0336 | -- | 0.326 | -- | -42.44 | -43.50 | -43.67 | -45.25 | -- | -- | -1,261.86 | -5,058.82 | -- | -- | 0.00 | -- | 997.63 | 93.78 | 11.41 | -- | -- | -- |
| Probiotec Ltd | 221.22m | 8.69m | 232.58m | 111.00 | 27.55 | 2.63 | 9.71 | 1.05 | 0.1038 | 0.1038 | 2.64 | 1.09 | 0.9483 | 7.03 | 6.99 | -- | 3.72 | 4.58 | 5.36 | 5.94 | 29.95 | 30.21 | 3.93 | 5.73 | 1.09 | 3.33 | 0.4937 | 47.90 | 17.39 | 23.10 | -19.61 | 20.84 | 12.97 | 18.77 |
| Cogstate Ltd | 64.16m | 8.52m | 239.99m | 61.00 | 30.70 | 4.09 | 18.79 | 3.74 | 0.0456 | 0.0456 | 0.3476 | 0.3422 | 0.7757 | -- | 5.58 | -- | 10.30 | 6.01 | 13.84 | 9.22 | 54.69 | 51.50 | 13.28 | 7.26 | -- | -- | 0.0135 | 0.00 | -8.62 | 7.25 | -52.56 | -- | -5.06 | -- |
| Botanix Pharmaceuticals Ltd | 200.38k | -10.02m | 370.16m | 1.00 | -- | 8.01 | -- | 1,847.28 | -0.0072 | -0.0072 | 0.0002 | 0.0293 | 0.0059 | -- | 1.09 | -- | -29.28 | -67.71 | -32.25 | -81.15 | -- | -- | -5,002.57 | -8,798.51 | 8.14 | -138.17 | 0.00 | -- | 351.94 | -6.25 | 30.50 | -- | -- | -- |
| Opthea Ltd | 180.93k | -249.70m | 410.94m | 5.00 | -- | -- | -- | 2,271.23 | -0.4786 | -0.4786 | 0.0004 | -0.1094 | 0.0007 | -- | 0.1772 | -- | -100.84 | -90.04 | -116.05 | -100.93 | -99.74 | -197.19 | -138,008.10 | -69,641.71 | -- | -29.64 | 1.35 | -- | 19.55 | -34.31 | -53.55 | -- | -3.82 | -- |
| PYC Therapeutics Ltd | 21.54m | -21.65m | 452.61m | 23.00 | -- | 12.11 | -- | 21.01 | -0.006 | -0.006 | 0.0062 | 0.008 | 0.6034 | -- | 2.48 | -- | -60.70 | -41.67 | -81.23 | -46.95 | -- | -- | -100.60 | -178.69 | -- | -50.32 | 0.0174 | -- | -1.11 | 218.52 | -64.39 | -- | 18.46 | -- |
| Immutep Ltd | 256.62k | -40.50m | 499.31m | 19.00 | -- | 4.32 | -- | 1,945.72 | -0.0394 | -0.0394 | 0.0003 | 0.0973 | 0.0025 | -- | 2.48 | -- | -38.61 | -36.31 | -41.57 | -39.21 | -- | -- | -15,782.59 | -919.13 | -- | -- | 0.0138 | -- | -24.64 | -51.34 | -23.86 | -- | 47.40 | -- |
| Mayne Pharma Group Ltd | 278.45m | -258.82m | 578.51m | 900.00 | -- | 1.01 | -- | 2.08 | -3.18 | -2.99 | 3.43 | 6.74 | 0.2105 | 0.8192 | 1.37 | -- | -19.56 | -14.47 | -26.66 | -18.05 | 68.05 | 50.60 | -92.95 | -64.69 | 1.30 | -5.68 | 0.0626 | -- | 20.75 | -18.54 | -51.49 | -- | 18.41 | -- |
| Imugene Ltd | 0.00 | -89.24m | 614.86m | 0.00 | -- | 3.09 | -- | -- | -0.0132 | -0.0132 | 0.00 | 0.0272 | 0.00 | -- | -- | -- | -40.29 | -26.64 | -43.53 | -28.00 | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -0.1207 | -- | -- | -- |
| Clinuvel Pharmaceuticals Limited | 87.29m | 30.15m | 754.92m | 16.00 | 25.85 | 4.23 | 24.24 | 8.65 | 0.5825 | 0.5825 | 1.69 | 3.56 | 0.4693 | -0.9514 | 7.35 | -- | 16.21 | 21.25 | 18.57 | 23.55 | 109.28 | -- | 34.54 | 41.84 | 6.43 | 14.53 | 0.006 | 7.44 | 24.27 | 26.14 | 46.58 | 18.27 | 68.74 | 20.11 |
| Clarity Pharmaceuticals Ltd | 0.00 | -30.56m | 935.45m | -- | -- | 14.92 | -- | -- | -0.1167 | -0.1167 | 0.00 | 0.2017 | 0.00 | -- | -- | -- | -41.34 | -- | -45.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.57 | -- | -- | -- |
Data as of May 02 2024. Currency figures normalised to Clinuvel Pharmaceuticals Ltd's reporting currency: Australian Dollar AUD
8.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 1.59m | 3.18% |
| Vanguard Investments Australia Ltd.as of 31 Mar 2024 | 722.44k | 1.44% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 457.76k | 0.91% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 453.75k | 0.91% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 357.35k | 0.71% |
| DFA Australia Ltd.as of 31 Mar 2024 | 244.12k | 0.49% |
| AllianceBernstein Ltd.as of 31 Dec 2023 | 214.79k | 0.43% |
| BlackRock Asset Management North Asia Ltd.as of 31 Jan 2024 | 118.29k | 0.24% |
| Charles Schwab Investment Management, Inc.as of 04 Apr 2024 | 86.03k | 0.17% |
| Evelyn Partners Investment Management LLPas of 29 Feb 2024 | 47.44k | 0.10% |
More ▼
Data from 31 Dec 2023 - 24 Apr 2024Source: FactSet Research Systems Inc.
